Exploring the Role of Cannabinoids in pain Management and Inflammation

Divya Bhawari[1*], Dr. Manisha Nangude[2], Swati Wakchaure[3], Sanjana Bhere [4]

[1,4] Student, Shivajirao S. Jondhle college of Pharmacy, Asangaon, Thane -421601 Maharashtra, India.*

[2]Prof.Shivajirao S. Jondhle college of Pharmacy, Asangaon, Thane -421601 Maharashtra, India.

[3,] Asst.Prof. Shivajirao S. Jondhle college of Pharmacy, Asangaon, Thane -421601 Maharashtra, India.

**Corresponding Author: Dr Manisha Nangude, Shivajirao S. Jondhle college of pharmacy, Asangaon, Thane -421601 Maharashtra, India.*

Abstract: Cannabinoids, which are active compounds present in *Cannabis sativa*, have once again become a potent treatment option for managing pain, inflammation, and other health conditions. This article thoroughly examines the endocannabinoid system, the mechanisms through which cannabinoids work, and the therapeutic benefits of cannabinoids, including delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). It discusses the clinical applications of cannabinoids in the management of chronic pain, inflammatory conditions, and palliative care, emphasizing their potential to reduce reliance on opioids and improve quality of life. The article also addresses considerations and challenges, such as side effects, regulatory issues, and individual differences. It explores future directions, including personalized medicine using pharmacogenomics, combination therapies, and innovative delivery methods. This review offers a comprehensive analysis of cannabinoid research, identifying areas for further investigation and potential paths for therapeutic progress.

Keywords: Cannabinoids, CBD, Inflammation, Pain Management, THC.

INTRODUCTION

Fig: Cannabis leaves and seeds

Cannabis sativa, an ancient botanical marvel, has reemerged as a therapeutic powerhouse, harnessing its bioactive compounds to alleviate pain and inflammation. This revered plant, with a lineage trac ing back millennia, offers renewed hope for individuals beset by intractable conditions.

Historically, cannabis has been a trusted ally in combating chronic pain, inflammation, anxiety, and other afflictions, with ancient civilizations – the Chinese, Egyptians, and Greeks – tapping into its medicinal properties. [1]

A member of the Cannabaceae family (Magnoliopsida, Urticales), *Cannabis sativa* boasts an intricate chemical architecture, yielding active compounds in diverse concentrations and proportions. Genomic background, growing conditions, and climate converge to create chemical varieties or chemovars. [2]

These chemovars harbour an impressive array of cannabinoids – over 100 distinct compounds. Delta-9-tetrahydrocannabinol (THC) and cannabidiol

(CBD) take centre stage, accompanied by cannabinol, cannabinoid acids, cannabigerol, and cannabidivarin. [3,4] Each cannabinoid exhibits unique pharmacological properties.

Research shows cannabis effectively treats various conditions, including pain, inflammation, anxiety, and psychosis.

The interaction between THC, CBD, and other phytocannabinoids, terpenoids, and flavonoids has the potential to revolutionise pain management. [5,6]

MECHANISM OF ACTION

Endocannabinoid System:
The endocannabinoid system (ECS) is a multifaceted network regulating pain and inflammation homeostasis, comprising cannabinoid receptors (CB1 and CB2), endocannabinoids (anandamide, 2-AG), and metabolic enzymes.[7]

CB1 Receptors:
Primarily Situated in the central nervous system (CNS), CB1 receptors play a role in pain regulation by decreasing the sensation of pain. Glutamate and substance P, two neurotransmitters linked to pain, are inhibited when CB1 receptors are activated. CB1 receptors also control spinal cord synaptic plasticity and descending pain modulation pathways, which enhances their analgesic effects. [8]

CB2 Receptors:
CB2 receptors, predominantly located in the immune system, are associated with anti-inflammatory responses. Activation of CB2 receptors inhibits the production of pro-inflammatory cytokines and chemokines, reducing inflammation and its associated pain. CB2 receptors also regulate immune cell activation and cytokine production, further contributing to their anti-inflammatory effects. [9,10]

Interaction with Neurotransmitters:
Cannabinoids interact with neurotransmitters involved in pain signaling, including GABA (inhibitory neurotransmitter), enhancing its release to reduce pain; glutamate (excitatory neurotransmitter), decreasing its release to reduce pain transmission; and substance P (pain-related neurotransmitter), reducing its release to alleviate pain. This relation contributes significantly to the analgesic effects of cannabinoids. [11]

Anti-Inflammatory Properties:
Cannabinoids produce anti-inflammatory properties by inhibiting the production of pro-inflammatory cytokines and chemokines, similar as TNF- α and IL-1β. This reduction in inflammation leads to decreased pain perception, making cannabinoids potential therapeutic agents for inflammatory diseases. [12]

TYPES OF CANNABINOIDS

1) 9-Tetrahydrocannabinol (THC): Multifaceted Therapeutic Agent.



Fig: Structure of THC

Δ9-THC, cannabis' primary psychotropic component, activates Cannabinoid Receptor 1 (CB1), inducing psychoactive effects, hypolocomotion, hypothermia, catalepsy, and analgesic properties. THC's activation of Cannabinoid Receptor 2 (CB2) yields neuroprotective, antispasmodic, and anti-inflammatory effects, showcasing its potential in managing neurological disorders. [13,14]

2) Cannabidiol (CBD): Non-Psychoactive Therapeutic Agent.



Fig: Structure of CBD

The non-psychoactive compound CBD regulates immune function and has low affinity for interacting with CB1 and CB2 receptors. It functions as a negative allosteric modulator. Its anti-inflammatory, anti-convulsant, anxiolytic, and neuroprotective properties are not dependent on CB receptors, indicating its potential in treating anxiety and seizure disorders.[15]

Other Cannabinoids:

- Cannabigerol (CBG): Non-Psychoactive Therapeutic Agent.



Fig: Structure of CBG

CBG selectively inhibits Anandamide (AEA) reuptake, enhancing ECS tone. CBG activates α2-adrenergic receptors, moderately blocks serotonin 5HT1A receptors, and exhibits antiproliferative, antibacterial, and anti-glaucoma properties, demonstrating its potential in treating prostate cancer and bladder pain. [14]

- Cannabichromene (CBC): Potent Anti-Inflammatory Agent



Fig: Structure of Cannabichromene

Cannabichromene (CBC) is a powerful anti-inflammatory substance. It is the most prevalent phytocannabinoid and has limited interaction with CB1 and CB2 receptors. CBC influences the endocannabinoid system (ECS) by blocking the uptake of AEA, displaying significant anti-inflammatory properties in animal studies, and enhancing the analgesic effects of Δ9-THC. [14,15]

CLINICAL APPLICATION

1) Chronic Pain Management:
Cannabinoids have excellent potential in treating long-lasting pain, offering a fresh perspective on conditions that usually do not respond well to traditional treatments. Included in these circumstances are fibromyalgia, neuropathic pain, persistent lumbar pain, and pain related to cancer.[16] Cannabinoids function by interacting with the body's endocannabinoid system, reducing pain signals and sensation through their impact on CB1 and CB2 receptors. There are numerous benefits to using cannabinoids for managing chronic pain. They aid in reducing how pain is felt and communicated, possess anti-inflammatory qualities, improve mood and cognitive abilities, promote better sleep, and lower reliance on opioids. Clinical trials consistently demonstrate their effectiveness in decreasing the intensity and occurrence of pain. Cannabinoids help alleviate pain and improve the quality of life for individuals with chronic pain conditions by modifying the immune response and decreasing inflammation. Using cannabinoids for chronic pain has advantages such as decreasing pain, reducing inflammation, enhancing mood and cognitive abilities, improving sleep quality, and lowering the use of opioids. Additionally, cannabinoids have shown effectiveness in decreasing inflammation, which is a frequent contributor to long-term pain. [17,18]

2) Inflammatory Conditions:
Cannabinoids have anti-inflammatory properties, which are valuable for treating conditions like multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, and psoriasis. They function by inhibiting the production of pro-inflammatory cytokines and chemokines, leading to a reduction in inflammation and associated pain. [19,20]
The use of cannabinoids for treating inflammatory conditions has benefits such as their ability to regulate the immune response, inhibit immune cell[6] activation, and reduce the production of inflammatory mediators. [21] This makes cannabinoids a promising option for treating inflammatory conditions, particularly those that don't respond well to traditional treatments. Additionally, cannabinoids offer neuroprotective effects that protect against damage caused by inflammation and oxidative stress. Conditions like multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, psoriasis, and neurodegenerative diseases could potentially benefit from cannabinoid treatment. [22,23]

3) Palliative Care:
In palliative care settings, cannabinoids improve symptom management for patients with serious illnesses, enhancing their quality of life. [24, 25] They address pain, nausea, loss of appetite, and anxiety associated with cancer and other advanced illnesses. [26] The benefits of cannabinoids in palliative care include pain relief, nausea and vomiting reduction, appetite stimulation, anxiety and depression reduction, improved sleep quality, and enhanced overall well-being. Cannabinoids provide relief from distressing symptoms, allowing patients to maintain their dignity and quality of life. Their therapeutic benefits extend to end-of-life care, providing comfort and relief to patients in their final stages of life.

Cannabinoids have a positive impact on the psychological well-being of patients, reducing anxiety and depression, and promoting relaxation and sleep. This makes them a valuable adjunct to traditional palliative care therapies, enhancing the overall care and support provided to patients with advanced illnesses. [27,28,29]

CONSIDERATIONS AND CHALLENGES

Side Effects:
Cannabinoids, especially tetrahydrocannabinol (THC), can lead to various side effects that may limit their therapeutic usefulness. One common side effect is dizziness, which can be particularly problematic for individuals with mobility challenges or those at risk of falling. Another concern is sedation, which can worsen existing fatigue or interfere with other medications. [30] Cognitive impairment is a major issue, especially with long-term THC use, affecting areas like attention, memory, and decision-making, potentially hindering daily activities. [31,32] THC's psychoactive effects can also trigger anxiety, paranoia, or psychosis in vulnerable individuals.[33]
Changes in appetite, weight, and metabolism are also possible, which may be beneficial for some patients but detrimental for others. Additional side effects include dry mouth, red eyes, and increased heart rate.[34] The intensity and occurrence of these side effects vary based on individual factors, dosage, and consumption method. While some may experience mild and temporary effects, others may face more severe and lasting problems. Additionally, the risk of cannabinoid withdrawal syndrome marked by irritability, anxiety, and sleep disturbances adds to the need for careful monitoring and useuse. [35]

Regulatory Issues:
The varying legal status of cannabis and cannabinoids presents major obstacles for both research and treatment. [36] Differences in regulations between countries and even within different states complicate the creation of standardised therapeutic guidelines. In the United States, cannabis is classified as a Schedule I substance, which significantly limits access to research funding and makes it more difficult to gain approval from institutional review boards for studies.[37] This classification also restricts healthcare providers from prescribing cannabinoids, often forcing patients to rely on unregulated products or travel to states where medical cannabis programs are available.
Additionally, the lack of standardisation in cannabis products and inconsistent labelling make it harder to make informed treatment decisions. To support research, improve quality control, and ensure safe access to cannabinoid therapies, evolving regulatory frameworks are necessary. Clear guidelines for the cultivation, processing, and labelling of cannabis products are critical to ensure consistency and potency. Policymakers must also address the conflicts between federal and state laws to establish a unified, patient-focused approach to cannabinoid therapy.

Individual variability:
The effectiveness of cannabinoids can vary significantly among individuals due to genetic factors, specific medical conditions, and concurrent medications. Genetic differences in the cannabinoid receptor genes, CNR1 and CNR2, may affect how individuals respond to cannabinoids.[38] Additionally, the ability of cannabinoids to manage chronic pain, inflammation, or other conditions depends on the underlying pathology and disease severity. [39] Concurrent medications, like opioids or antidepressants, can also interact with cannabinoids, impacting their effectiveness and safety. Individual variances in metabolism and pharmacokinetics can also influence cannabinoid levels and effects.[40] For instance, variations in the cytochrome P450 enzyme system can impact THC metabolism. Furthermore, factors such as age, gender, and body composition might affect cannabinoid pharmacodynamics and pharmacokinetics.

Need for Research:
The full potential of cannabinoids in providing beneficial effects is currently not fully realised due to substantial research gaps. Standardised dosing and definitions are essential to ensure consistent therapeutic outcomes and maximise their effectiveness. Healthcare providers require evidence-based treatment guidelines to appropriately administer cannabinoids for various medical conditions. It is crucial to conduct comprehensive clinical trials to establish the efficacy[4], safety, and optimal dosing regimens of cannabinoids, as well as to explore their interactions with other medications and their impact on vulnerable groups, including expecting mothers, minors, and individuals with compromised health. [41]
In order to address these knowledge gaps, research efforts should focus on understanding the body's

processing of cannabinoids and their effects, conducting relevant clinical trials for specific medical conditions, studying the interactions of cannabinoids with other substances and their combined effects, developing new formulations and administration methods for cannabinoids, and examining the long-term effects and potential risks associated with cannabinoids.

Furthermore, researchers should explore the potential of cannabinoids in addressing the opioid crisis, improving mental health outcomes, enhancing palliative care.[42] reducing healthcare utilisation, improving overall quality of life, and providing insights into economic outcomes and healthcare policy.

Addressing these research needs will significantly enhance our understanding of the therapeutic potential of cannabinoids, ultimately leading to evidence-based practice and improved patient care.

FUTURE DIRECTIONS

1) Personalized Medicine through Pharmacogenomics:

Pharmacogenomics has the potential to revolutionise cannabinoid treatment by tailoring medications to individual genetic profiles, maximising effectiveness, and minimising side effects. By examining how genes influence drug response, pharmacogenomics can predict how genetic variations in cannabinoid receptors such as Cannabinoid Receptor 1 (CB1) and Cannabinoid Receptor 2 (CB2), as well as metabolising enzymes like Fatty Acid Amide Hydrolase (FAAH), affect cannabinoid pharmacokinetics and pharmacodynamics. Research has already identified various genetic variations associated with cannabinoid response, including those in the CNR1 gene (Cannabinoid Receptor 1 Gene) and the FAAH gene. Further studies are necessary to fully understand the pharmacogenomics of cannabinoids and develop genetic testing for personalised treatment. Personalised medicine in cannabinoid treatment has the potential to improve treatment outcomes through targeted therapies, reduce the risk of adverse reactions and side effects, enhance patient safety and health, increase the effectiveness of cannabinoid medications, and reduce healthcare costs by avoiding trial-and-error approaches.[43]

2) Combination Therapies :

Combination Therapies:

Combining cannabinoids with traditional analgesics, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), or anti-inflammatory medications may offer enhanced therapeutic outcomes and synergistic benefits. Research has shown that cannabinoids can interact with opioids, specifically Opioid Receptor Agonists, and NSAIDs, potentially reducing opioid usage and minimising side effects. [44]

Combination Therapy Studies:

Studies have investigated combination therapies involving cannabinoids and opioids, demonstrating improved analgesic efficacy and reduced opioid tolerance. Other research has explored combining cannabinoids with NSAIDs, showing enhanced anti-inflammatory effects and reduced gastrointestinal toxicity. [45]

Potential Combination Therapies:

The potential combination therapies include the use of cannabinoids and opioids for pain management, the combination of cannabinoids with NSAIDs for dealing with inflammation. [46] and the use of cannabinoids alongside mood stabilisers, especially those that target serotonin regulation, such as widely prescribed antidepressants, for the treatment of mental health disorders like depression and anxiety.

3) Novel Delivery Methods:

Innovative delivery systems can significantly improve the bioavailability and targeted delivery of cannabinoids for pain management. Transdermal patches, inhalers, and nanoparticle-based delivery systems offer promising approaches for enhancing cannabinoid delivery.

Other Novel Delivery Methods:

Innovative delivery methods also include topical creams and gels that are formulated for targeted application, oral mucosal delivery systems for rapid absorption, and implantable devices for extended release. These sophisticated delivery systems have the capacity to improve patient results and overall quality of life. [47]

Examples: Mary's Medicinals Transdermal Patch (THC, CBD), Syqe Medical Inhaler (THC, CBD), MedReleaf Topical Cream (THC, CBD), HempCann's CBD Implantable Device, Sativex oromucosal spray (THC, CBD).

CONCLUSION

Cannabinoids show remarkable potential in treating intricate health conditions, boasting impressive pain-relieving, anti-inflammatory, and neuroprotective properties. By alleviating diverse pain types and curbing opioid dependence and overdose risks, cannabinoids complement traditional pain management strategies. Ongoing research will unravel their complexities, paving the way for personalised and integrative pain management solutions.

Unlocking their full potential requires further investigation into optimal dosing, delivery methods, and synergistic therapies. Effective integration relies on sustained research, education, and cross-disciplinary collaboration.

By harnessing cannabinoids' therapeutic benefits, patients with chronic pain and inflammation can experience significantly improved quality of life, leading to enhanced health outcomes, reduced healthcare costs, and groundbreaking treatment options.

REFERENCES

[1] Abrams et al. (2018). Cannabis, cannabinoids, and pain relief. Clinical Pharmacology and Therapeutics, 103(5), 799-808.

[2] Lewis, M.A.; Russo, E.B.; Smith, K.M. (2018). Pharmacological Foundations of Cannabis Chemovars. Planta Med. , 84, 225–233.

[3] Gaoni, Y.; Mechoulam, R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. J. Am. Chem. Soc. 1964, 86, 1646–1647.

[4] ElSohly, M.A.; Slade, D. (2005). Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci., 78, 539–548.

[5] Russo, E.; Guy, G.W. (2005). A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses, 66, 234–246.

[6] Russo, E.B. Taming (2011). THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br. J. Pharmacol. 163, 1344–1364

[7] Pacher et al. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58(3), 389-462.

[8] Mackie et al. (2015). Cannabinoid receptors and pain. Journal of Pain Research, 8, 277-291.

[9] Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci 1999; 96: 14228-33.

[10] Guimarães et al. (2018). Cannabinoids and the immune system. Journal of Leukocyte Biology, 103(5), 789-799.

[11] Patel et al. (2017). The endocannabinoid system and pain. Journal of Pain Research, 10, 1275-1288.

[12] Nagarkatti et al. (2018). Cannabinoids and inflammation. Journal of Cannabis Research, 1(1), 12.

[13] Bhatti FI, Mowforth OD, Butler MB, Bhatti AI, Adeeko S, Akhbari M, et al. Systematic review of the impact of cannabinoids on neurobehavioral outcomes in preclinical models of traumatic and nontraumatic spinal cord injury. Spinal Cord. 2021 ; 59:1221–39.

[14] Coelho MP, Duarte P, Calado M, Almeida AJ, Reis CP, Gaspar MM. The current role of cannabis and cannabinoids in health: a comprehensive review of their therapeutic potential. Life Sci. 2023;329.

[15] Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, et al. (2017). State of the art and new challenges for therapeutic applications. Pharmacol Ther.

[16] Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV et al (2015). Cannabinoids for medical use. JAMA 313: 2456.

[17] Martin-Sanchez et al. (2019). Cannabinoids for chronic pain: A systematic review and meta-analysis. Journal of Clinical Pharmacology, 59(10), 1331-1342.

[18] Lu et al. (2019). Cannabinoids for chronic pain management: A review of clinical effectiveness. Journal of Clinical Medicine, 8(11), 1935.

[19] Guindon, J., & Hohmann, A. G. (2011). The endocannabinoid system and pain. Journal of Pain Research, 4, 121-145.

[20] Nagarkatti, P., et al. (2009). Cannabinoids as novel anti-inflammatory agents. Future Medicinal Chemistry, 1(7), 1333-1349.

[21] Croxford, J. L., & Miller, L. E. (2003). Cannabinoids and multiple sclerosis. Journal of Cannabis Research, 5(2), 161-171.

[22] Fernández-Ruiz, J., et al. (2013). Cannabinoids in neurodegenerative disorders:

therapeutic perspective. Molecular Neurobiology, 48(1), 1-25.

[23] García, C., et al. (2011). Cannabinoids and neurodegenerative diseases. Journal of Neuroimmune Pharmacology, 6(4), 593-605.

[24] World Health Organization. Palliative care. Available at https://www.who.int/news-room/fact-sheets/detail/palliative-care Accessed August 1, 2020.

[25] Pastrana T, Junger S, Ostgathe C, Elsner F, Radbruch L (2008). A matter of definition - Key elements identified in a discourse analysis of definitions of palliative care. Palliat Med, 22:222–232.

[26] Wilsey et al. (2015). Cannabis for cancer pain. Journal of Pain and Symptom Management, 49(3), 538-546.

[27] Nurmikko et al. (2018). Cannabis in palliative care. Journal of Pain Research, 11, 1275-1285.

[28] Johnson et al. (2018). Cannabis and cannabinoids in palliative care. Journal of Palliative Medicine, 21(5), 631-638.

[29] Abrams et al. (2017). Medical cannabis in palliative care. Journal of Palliative Medicine, 20(9), 1025-1032.

[30] Guimarães, F. S., et al. (2020). Cannabis and cannabinoids for pain management. Journal of Pain Research, 13, 1975-1987.

[31] Ranganathan, M., & D'Souza, D. C. (2017). The acute effects of cannabinoids on memory. Current Addiction Reports, 4(2), 148-155.

[32] Crean, R. D., et al. (2011). Cannabis use and cognitive performance. Journal of Clinical Pharmacology, 51(3), 318-327.

[33] Boggs, D. L., et al. (2018). The effects of cannabis and cannabinoids on psychosis. Journal of Clinical Psychopharmacology, 38(3), 269-274.

[34] Kalant, H. (2004). Adverse effects of cannabis. Journal of Clinical Pharmacology, 44(11), 1145-1155.

[35] Budney AJ, Hughes JR. (2006) The cannabis withdrawal syndrome. Curr Opin Psychiatry.19:233–8.

[36] National Academies of Sciences, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids.

[37] National Institute on Drug Abuse. (2020). Researching Marijuana and Its Therapeutic Potential.

[38] Pertwee, R. G. (2008). Diverse CB1 and CB2 receptor pharmacology. British Journal of Pharmacology, 153(2), 199-215.

[39] Martin-Sanchez, E. (2018). Cannabinoids for chronic pain treatment. Journal of Clinical Psychopharmacology, 38(3), 255-265.

[40] Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. Chemistry and Biodiversity, 4(8), 1770-1804.

[41] Whiting et al. (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA, 313(24), 2456-2473.

[42] Wilkinson et al. (2019). Cannabinoids for the Treatment of Mental Health Disorders: A Systematic Review. Lancet Psychiatry, 6(12), 1045-1055.

[43] Babayeva, M.; Loewy, Z.G. (2022) Cannabis Pharmacogenomics: A Path to Personalized Medicine. Journal of Personalized Medicine, 12, 1459.

[44] Abrams, D. I., & Guzman, M. (2018). Cannabinoids and opioid receptor agonists: Combination therapy for pain relief. Clinical Pharmacology and Therapeutics, 103(5), 885-893.

[45] Mukherjee, et al. (2019). Cannabinoids and NSAIDs: Synergistic therapy for inflammation. Journal of Cannabis Research, 1(1), 1-11.

[46] Wilkinson, et al. (2019). Cannabinoids and NSAIDs: A review of the evidence for combination therapy. Journal of Clinical Pharmacology, 59(10), 1320-1328.

[47] Bruni, N., Della Pepa, C., Oliaro-Bosso, S., Pessione, E., Gastaldi, D., & Dosio, F. (2018). Cannabinoid Delivery Systems for Pain and Inflammation Treatment. Molecules (Basel, Switzerland), 23(10), 2478.